Potential adverse effects of proton pump inhibitors in the elderly

Clinical Geriatrics

Volumn 18, Issue 7-8, 2010, Pages 24-31

  Kapadia, Ami ^a   Wynn, Daisy ^b   Salzman, Brooke ^c  

^a Grand Junction VA Medical Center   (United States)

^b Stress Reduction and Relaxation Program   (United States)

^c THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CLOPIDOGREL; CYANOCOBALAMIN; DIGOXIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; LANSOPRAZOLE; NIFEDIPINE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; WARFARIN;

ABDOMINAL PAIN; AGED; ALLERGIC REACTION; ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; BLEEDING; CLOSTRIDIUM DIFFICILE INFECTION; COMA; COMMUNITY ACQUIRED PNEUMONIA; CYANOCOBALAMIN DEFICIENCY; DEATH; DIARRHEA; DIGOXIN BLOOD LEVEL; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG INDICATION; DRUG METABOLISM; DRUG MISUSE; DRUG TOLERANCE; DRUG USE; DUODENUM ULCER; FOOD ALLERGY; FOREARM FRACTURE; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER PYLORI; HIP FRACTURE; HUMAN; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; POLYPHARMACY; PRESCRIPTION; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SHOCK; SIDE EFFECT; SPINE FRACTURE; STOMACH ULCER; TREATMENT DURATION; TREATMENT INDICATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WRIST FRACTURE; ZOLLINGER ELLISON SYNDROME;

EID: 77956915381     PISSN: 10951598     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Top 200 generic drugs by retail dollars in 2007. http://drugtopics.modern medicine.com/drugtopics/data/articlestandard//drugtopics/102008/500218/ article.pdf. Accessed June 21, 2010.
2. Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ. Proton pump inhibitors: A survey of prescribing in an Irish general hospital. Int J Clin Pract 2005;59:31-34.
3. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharm Ther 2000;25:333-340.
4. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-3122.
5. Parente F, Cucino C, Gallus S, et al. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: A 1-month survey. Aliment Pharamacol Ther 2003;17:1503-1506.
6. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001;23:116-117.
7. Pohland CJ, Scavnicky SA, Lasky SS, Good CB. Lansoprazole overutilization: Methods for step-down therapy. Am J Manag Care 2003;9:353-358.
8. Shams D, Siddiqui NH, Heif, MM. Gastroesophageal reflux disease in older adults: What is the difference? Clinical Geriatrics 2009;17(3):32-37.
9. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004;57:422-428.
10. Vanderhoff BT, Tahboub RM. Proton pump inhibitors: An update. Am Fam Physician 2002;66:273-280.
11. Pham CQ, Regal RE, Bostwick TR, et al. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006;40:1261-1266.
12. Shi S, Klotz U. Proton pump inhibitors: An update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-951. Published Online: August 5, 2008.
13. Detsky ME, Juurlink DN. Does gastric acid suppression increase the risk of community- acquired pneumonia? CMAJ 2005;172(3):331.
14. Bhatt DL, Scheiman J, Abraham NS, et al; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008;118:1894-1909. Published Online: October 3, 2008.
15. Manoharan T, Darzins P. Acid suppression in the elderly. Australasian Journal on Ageing 2006;25(3):164-166.
16. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007;5(4):345-351.
17. Sutfin T, Balmer K, Boström H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989;11:176-184.
18. Kiley CA, Cragin DJ, Roth BJ. Omeprazole-associated digoxin toxicity. South Med J 2007;100(4):400-402.
19. Oosterhuis B, Jonkman JH, Anderson T, et al. Minor effect of multiple dose omperazole on the pharmacokinetics of digoxin after a single oral dose. B J Clin Pharmacol 1991;32:569-572.
20. McCarthy DM, McLaughlin TP, Griffis DL, Yazdani C. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cythochrome. Am J Ther 2003;10:330-340.
21. Early communication about ongoing safety review of clopidogrel bisulfate (marketed as Plavix). U.S. Food and Drug Administration. http://www.fda.gov/ Drugs/Drug Safety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInfo mationforHeathcareProfessionals/ucm079520.htm. Updated February 23, 2010. Accessed June 28, 2010.
22. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008;48:475-484. Published Online: February 26, 2008.
23. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148e1-148.e5. Published Online: November 6, 2008.
24. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.
25. Gilard M, Arnaud B, Le Gal C, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006;4:2508-2509. Published Online: August 8, 2006.
26. Ho MP, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 2009;301:937-944.
27. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton pump inhibitors: A cohort study. Ann Intern Med 2010;152 (6):337-345.
28. Stockl KM, Le L, Zakharyan A, et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med 2010;170(8):704-710.
29. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103:2308-2313. Published Online: August 12, 2008.
30. Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for clostridium difficile-associated diarrhea. Aliment Pharmacol Ther 2006;24:613-619.
31. Dial S, Alrasadi K, Manoukian C, et al. Risk of clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ 2004;171:33-38.
32. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-2056. Published Online: May 17, 2007.
33. Shah S, Lewis A, Leopold D, et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000;93:175-181.
34. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for clostridium difficile diarrhoea. J Hosp Infect 2003;54:243-245.
35. Lowe DO, Mamdani MM, Kopp A, et al. Proton pump inhibitors and hospitalization for clostridium difficile-associated disease: A population-based study. Clin Infect Dis 2006;43:1272-1276. Published Online: October 13, 2006.
36. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170(9):784-790.
37. Untersmayr E, Bakos N, Scholl I, et al. Anti-ulcer drugs promote IgE formation toward dietary antigens in adult patients. FASEB 2005;19(6):656-658. Published online January 25, 2005.
38. Untersmayr E, Schöll I, Swoboda I, et al. Antacid medication inhibits digestion of dietary proteins and causes food allergy: A fish allergy model in BALB/c mice. J Allergy Clin Immunol 2003;112:616-623.
39. Laheij RJ, Sturkenoboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292(16):1955- 1960.
40. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: A population-based case-control study. Arch Intern Med 2007;167:950-995.
41. Sarkar M, Hennessy S, Yang Y. Proton-pump inhibitor and the risk for communityacquired pneumonia. Ann Intern Med 2008;149:391-398.
42. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009;301(20):2120-2128.
43. Sataloff R. Community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2005;293:7:795-796.
44. Gregor JC. Acid suppression and pneumonia: A clinical indication for rational prescribing. JAMA 2004;292:16:2012-2013.
45. Yang YX, Lewis, JD, Epstein, S. Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953.
46. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006;79:76-83. Published Online: August 15, 2006.
47. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179:319-326.
48. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009;84(1):13-19. Published Online: November 21, 2008.
49. Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:208-214.
50. Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: Results from the Women's Health Initiative. Arch Intern Med 2010;170(9):765-771.
51. Johnson DA. Do ppis increase risk for hip fracture? Journal Watch. http://gastro enterology.jwatch.org/cgi/content/full/2007/105/1. Accessed June 21, 2010.
52. Fried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994;35:23-26.
53. Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000;30(1):29-33.
54. Laine L, Ahnen D, Mcclain C, et al. Review article: Potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14(6):651-668.
55. Force RW, Meeker AD, Cady PS, et al. Ambulatory care increased vitamin B12 requirement associated with chronic acid-suppression therapy. Ann Pharmacother 2003;37:490-493